HC Wainwright set a $5.00 price target on STRATA Skin Sciences (NASDAQ:SSKN) in a research report released on Wednesday. The brokerage currently has a buy rating on the medical device company’s stock.

Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered STRATA Skin Sciences from a strong-buy rating to a hold rating in a report on Wednesday, August 1st. Dawson James assumed coverage on STRATA Skin Sciences in a report on Tuesday, September 4th. They issued a buy rating on the stock.

SSKN traded up $0.13 during trading on Wednesday, reaching $2.66. The company’s stock had a trading volume of 13 shares, compared to its average volume of 201,531. STRATA Skin Sciences has a 52-week low of $1.09 and a 52-week high of $3.88. The firm has a market capitalization of $86.83 million, a PE ratio of 1.31 and a beta of 0.82. The company has a current ratio of 4.77, a quick ratio of 4.20 and a debt-to-equity ratio of 0.22.

STRATA Skin Sciences (NASDAQ:SSKN) last announced its quarterly earnings data on Tuesday, November 13th. The medical device company reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.03. STRATA Skin Sciences had a negative return on equity of 27.01% and a negative net margin of 63.07%. The company had revenue of $7.89 million for the quarter, compared to analyst estimates of $7.64 million. On average, sell-side analysts predict that STRATA Skin Sciences will post -0.2 EPS for the current year.

Hedge funds have recently bought and sold shares of the company. Macquarie Group Ltd. lifted its position in shares of STRATA Skin Sciences by 89.7% during the 2nd quarter. Macquarie Group Ltd. now owns 134,033 shares of the medical device company’s stock valued at $275,000 after acquiring an additional 63,393 shares during the period. Nantahala Capital Management LLC acquired a new stake in shares of STRATA Skin Sciences during the 2nd quarter valued at approximately $4,261,000. Renaissance Technologies LLC lifted its position in shares of STRATA Skin Sciences by 164.6% during the 2nd quarter. Renaissance Technologies LLC now owns 293,499 shares of the medical device company’s stock valued at $602,000 after acquiring an additional 182,579 shares during the period. Menora Mivtachim Holdings LTD. acquired a new stake in shares of STRATA Skin Sciences during the 2nd quarter valued at approximately $1,138,000. Finally, EAM Investors LLC acquired a new stake in shares of STRATA Skin Sciences during the 3rd quarter valued at approximately $830,000. Institutional investors own 27.48% of the company’s stock.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

Further Reading: 52-Week High/Low

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.